A5101098934- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Cardiac tumors and thrombi
- Lung Cancer Research Studies
- Prenatal Screening and Diagnostics
- Multiple Myeloma Research and Treatments
- BRCA gene mutations in cancer
- COVID-19 Clinical Research Studies
- Colorectal Cancer Screening and Detection
- Melanoma and MAPK Pathways
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer Research and Treatments
- Ethics and Legal Issues in Pediatric Healthcare
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Genetic factors in colorectal cancer
- Venous Thromboembolism Diagnosis and Management
- COVID-19 and healthcare impacts
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Brain Metastases and Treatment
- Healthcare cost, quality, practices
- Chemotherapy-related skin toxicity
Rajiv Gandhi Cancer Institute and Research Centre
2020-2024
Gandhi Medical College & Hospital
2020-2023
Creative Commons
2023
Background Colorectal cancer (CRC) is a heterogeneous disease morphologically, histologically, and molecularly. Most of the studies are on this molecular heterogeneity their clinicopathological correlation from western world. Very few have been done in India. Objectives The aims study were to evaluate clinical pathological profile CRCs, determine frequency subtypes correlate between features, association different CRC. Materials Methods A prospective noninvasive interventional was 50...
Background: Biomarker-driven lung adenocarcinomas involving alterations in oncogenic drivers such as EGFR, ALK, ROS1, and NTRK have witnessed a dramatic shift the therapeutic prognostic landscape owing to development of molecular targeted therapies. The recent approval selective RET inhibitor, selpercatinib, has led an ardent interest RET-rearranged non-small cell carcinoma (NSCLC). However, sequential single-gene testing cannot detect rearrangements accurately or characterize fusion...
Plasma cell dyscrasias are a mixed bag of plasma malignancies and include indolent monoclonal gammopathy undetermined significance (MGUS) at one end the spectrum aggressive leukemia other end. Multiple myeloma accounts for approximately 1–2% all cancers, 17% hematologic malignancies,[1] is reported to be more common in men than women.[1] Data from Surveillance, Epidemiology, End Results (SEER) Registry suggest an annual incidence 7 per 100,000 women year.[2] As Global Cancer Observatory...
Pazopanib is a multitargeted tyrosine kinase inhibitor used for the treatment of various solid tumor malignancies. Hair color change, particularly hair depigmentation, common side effect pazopanib therapy. However, it usually develops gradually over span few months. This article will provide comprehensive analysis depigmentation in patients treated with pazopanib, focusing on aspects this phenomenon, including its onset, possible causes, and potential implications therapy success....
Abstract Introduction: Afatinib, a second-generation EGFR TKI, was approved in 2015 for the treatment of metastatic NSCLC India. We aimed to evaluate clinical outcomes Afatinib therapy real-world setting. Patients and Methods: Electronic medical records 43 patients who received advanced EGFR-mutant were retrospectively reviewed. In total, analyzed whom 31 first-line therapy. Results: The patient population younger than Lux-Lung 3. Median PFS 15.03 months with 95% CI (7.8–18.3 months). At 14%...
The knowledge of oncogene addiction in non small cell lung carcinoma (NSCLC) involving EGFR, ALK and ROS1 genes has changed the therapeutic prognostic landscape NSCLC. rearranged NSCLC accounts for 10% these cases, with development approval TKIs (tyrosine kinase inhibitors) like crizotinib, it is imperative to detect same. Various variants are known occur resulting differential sensitivities because different protein stabilities. precise characterization hence important which can be achieved...
A 50-year-old female presented to our hospital with left-sided nipple discharge for the past 2 months. On evaluation, she was found have locally advanced invasive ductal cancer of left breast. Immunohistochemistry revealed estrogen, progesterone receptor status as negative and testing Her-2 3+. She underwent neoadjuvant chemotherapy TCH (trastuzumab, carboplatin, taxane) protocol followed by modified radical mastectomy, adjuvant radiotherapy, maintenance trastuzumab 1 year. Fourteen months...
Coronavirus disease 2019 (COVID-19) patients with malignancy are published worldwide but lacking in data from India.To characterize COVID-19 related mortality outcomes within 30 d of diagnosis HRCT score and RT-PCR Ct value-based viral load various solid malignancies.Patients included this study were an active or previous confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection the institute database. We collected on demographic details, baseline clinical conditions,...
e21199 Background: Mutations in the BRAF gene (0.8%-8% cases of NSCLC) comprise a molecularly heterogeneous group, with canonical V600E mutation as well myriad variants. Traditionally, diagnostics utilize modalities like specific IHC or allele real-time PCR for detection variant and may underestimate true prevalence non-V600E Broader panel next generation sequencing (NGS) testing be better modality detecting them this have potential therapeutic implications. This retrospective study patients...
We present a rare case of disseminated intravascular coagulation (DIC) as the initial manifestation metastatic carcinoma prostate. DIC is life-threatening condition characterized by systemic activation and widespread microvascular thrombosis, leading to organ dysfunction. Although commonly associated with hematological malignancies sepsis, its occurrence paraneoplastic syndrome in solid tumors extremely rare. Our highlights importance considering potential complication patients advanced...
We read with deep interest the review article published in previous issue of Cancer Research Statistics and Treatment authored by Ulhaq et al.[1] feel that this manuscript is utmost importance for practicing oncologists journal needs to be congratulated selecting publication highlight issue. After more than three decades oncology country, senior writer letter acutely aware lack knowledge among treating clinicians extreme dearth trained genetic counselors. Hereditary cancer contributes 5–10%...
Abstract Immune checkpoint inhibitor (ICI) restores an efficient antitumor T cell response against tumor cells fostering durable responses that can persist even after the treatment. However, these treatment effects manifest as unusual pattern of disease progression, pseudo-progression, or hyper-progression. Differentiating hyper progressive (HPD) from pseudo-progression has significant clinical implications and further decision-making for patient on ICI. HPD is a dramatic acceleration rate...